There are currently 1280 clinical trials in Cleveland, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cleveland Clinic, Cleveland Clinic Foundation, Case Western Reserve University and University Hospitals Cleveland Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
NCT06566079
Recruiting
This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
Register for Updates
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
NCT04010357
Recruiting
The purpose of this study is to: * Test how well the study medicine Abemaciclib, a CDK4/6 inhibitor, works to shrink lung cancer tumors in the body. * Test the safety of Abemaciclib when given to participants with small cell lung cancer (SCLC), large cell neuroendocrine lung cancer, extrapulmonary small cell cancers and other high grade neuroendocrine cancers of the lung. Specifically, this study is looking at SCLC, large cell neuroendocrine lung cancer, extrapulmonary small cell cancers and ot... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
06/03/2025
Locations: Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Small-cell Lung Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Small Cell Carcinoma
Register for Updates
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
NCT05484622
Recruiting
Vorasidenib in combination with pembrolizumab in participants with recurrent or progressive isocitrate dehydrogenase-1 (IDH-1) mutant Glioma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Cleveland Clinic, Cleveland, Ohio +1 locations
Conditions: Astrocytoma, Oligodendroglioma
Register for Updates
Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma
NCT05053659
Recruiting
The purpose of this study is to determine the correct dose and safety of combining two new cancer drugs, loncastuximab tesirine and venetoclax, as a treatment for relapsed or refractory B cell lymphoma.These drugs are used to treat some lymphomas, but have not yet been tested in combination for the treatment of lymphoma. The main goal of this study is to determine the safety of the combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Register for Updates
Infant Formula in Infants and Children With Cow's Milk Allergy
NCT06456541
Recruiting
This is a multi-center, randomized, double-blinded, placebo-controlled food challenge to be conducted in infants and children with confirmed IgE-mediated cow's milk allergy (CMA), followed by a 7-day open feeding of the experimental formula.
Gender:
ALL
Ages:
Between 3 months and 12 years
Trial Updated:
06/02/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Cow's Milk Allergy
Register for Updates
A Study of ZL-1310 in Participants With Selected Solid Tumors
NCT06885281
Recruiting
A Phase Ib/II, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Zai Lab Site 2024, Cleveland, Ohio
Conditions: Solid Tumors
Register for Updates
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
NCT03104491
Recruiting
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects. The Phase II portion of this study is to see what side effects are seen with medication after transplant. Inotuzumab ozogamicin is a combination of an antibody and chemotherapy which has been shown to have significant activity against relapsed/refractory acute... Read More
Gender:
ALL
Ages:
Between 16 years and 75 years
Trial Updated:
06/02/2025
Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio +1 locations
Conditions: Acute Lymphocytic Leukemia
Register for Updates
SELUTION4BTK Trial
NCT05055297
Recruiting
This study aims to demonstrate superior efficacy and equivalent safety of the SELUTION SLR™ DEB 014 compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the BTK arteries in CLTI patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities
Register for Updates
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
NCT03328078
Recruiting
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory (R/R) hematologic malignancies. This trial will be completed in four parts. In Part A1, emavusertib will be evaluated first in a dose escalating monotherapy setting to establish the safety and tolerability (complete). In Part A2, emavusertib will be evaluated... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
Register for Updates
Changes in Microbial Status From Dentate, Edentulous and After Dental Implant Placement
NCT06149585
Recruiting
The objectives of this study are to analyze the oral microbiome modulations occurring during the transition from partial (with some residual teeth) to full edentulous (without remaining teeth) status and implant placement in subjects affected by severe periodontitis; to evaluate if microbiome changes in relation to the used of different implant material/surface; and to assess the variance of the changes to determine the sample size for future longitudinal prospective studies.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/02/2025
Locations: Case Western Reserve University Department of Periodontics, Cleveland, Ohio
Conditions: Edentulous Mouth, Periodontal Diseases, Periodontitis, Adult, Microbial Colonization
Register for Updates
Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
NCT06150183
Recruiting
The purpose of this first-in-human study is to find out if BNT314 is safe when it is used alone in patients with different types of cancer. This is a dose escalation study in which patients will be assigned to multiple dose levels (DLs) of BNT314 given alone. By escalating the dose with a small group of patients, the Maximum Tolerated Dose (MTD) which is the highest dose with acceptable safety and manageable side effects, or the maximum administered dose (MAD) will be investigated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Advanced Malignant Solid Tumor
Register for Updates
Assessment of CCM in HF With Higher Ejection Fraction
NCT05064709
Recruiting
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio +1 locations
Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure
Register for Updates